EUVIMEDEUVIMED entdecken
Open Access

Peripheral immune checkpoint gene expression as diagnostic biomarkers in idiopathic pulmonary fibrosis.

Makbule Nihan Somuncu iD, Adil Zamani iD, Ayse Gul Zamani iD, Ayşe İnci iD, Mahmut Selman Yıldırım iD

Sarcoidosis vasculitis and diffuse lung diseases · 30.09.2026 · 43 (3) · 18872-18872

DOI: 10.36141/svdld.2026.18872 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Sarcoidosis vasculitis and diffuse lung diseases, erschienen am 30.09.2026. Verfasst von Makbule Nihan Somuncu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Medical Genetics Department, Medicine Faculty, Necmettin Erbakan University. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND AIM: Idiopathic pulmonary fibrosis (IPF) is a relatively rare and progressive fibrotic interstitial lung disease with limited annual incidence and poor prognosis. Increasing evidence suggests that immune dysregulation, including altered immune checkpoint and innate regulatory signaling pathways, may contribute to disease pathogenesis. This study aimed to investigate peripheral blood expression levels of PD-1, PD-L1, TIM-3, and TOLLIP genes and to evaluate their diagnostic potential in patients with IPF. METHODS: This case-control study included 20 IPF patients and 20 age-matched healthy controls. Gene expression levels were quantified using real-time quantitative polymerase chain reaction (RT-qPCR) and calculated using the ΔCt method. Diagnostic discrimination was assessed by receiver operating characteristic (ROC) analysis. RESULTS: PD-L1 (p < 0.001) and TOLLIP (p = 0.002) ΔCt values were significantly higher, indicating reduced relative gene expression. ROC analysis demonstrated strong diagnostic performance for PD-L1 (AUC = 0.883) and TOLLIP (AUC = 0.865). The combined PD-L1 + TOLLIP biomarker panel demonstrated superior diagnostic accuracy (AUC = 0.948). Internal validation using bootstrap resampling confirmed model stability (mean AUC = 0.950; 95% CI: 0.85-1.00). CONCLUSIONS: In conclusion, peripheral blood PD-L1 and TOLLIP expression levels are significantly downregulated in patients with idiopathic pulmonary fibrosis. The combined PD-L1 + TOLLIP biomarker panel demonstrated strong diagnostic discrimination (AUC = 0.948), supporting the potential clinical utility of peripheral immune regulatory gene signatures as minimally invasive biomarkers in IPF. Larger prospective studies are warranted to validate these findings and to explore their potential role in clinical decision-making.

Schlagwörter

idiopathic pulmonary fibrosisimmune checkpoint genesPD-L1TollipPD-1TIM-3peripheral blood gene expressiondiagnostic biomarkersminimally invasive biomarkersbiomarker panel

Autor:innen und Institutionen

  • Medical Genetics Department, Medicine Faculty, Necmettin Erbakan University.
  • Department of Chest Diseases, Faculty of Medicine, Necmettin Erbakan University.
  • Department of Pharmaceutical Microbiology, School of Pharmacy, İstanbul Medipol University.

ORCID-Profile: Makbule Nihan Somuncu, Adil Zamani, Ayse Gul Zamani, Ayşe İnci, Mahmut Selman Yıldırım

Zitieren

APA

Somuncu, M. N., Zamani, A., Zamani, A. G., İnci, A., & Yıldırım, M. S. (2026). Peripheral immune checkpoint gene expression as diagnostic biomarkers in idiopathic pulmonary fibrosis. Sarcoidosis vasculitis and diffuse lung diseases, 43(3), 18872-18872. https://doi.org/10.36141/svdld.2026.18872

Vancouver

Somuncu MN, Zamani A, Zamani AG, İnci A, Yıldırım MS. Peripheral immune checkpoint gene expression as diagnostic biomarkers in idiopathic pulmonary fibrosis. Sarcoidosis vasculitis and diffuse lung diseases. 2026;43(3):18872-18872. doi:10.36141/svdld.2026.18872

BibTeX
@article{Somuncu2026,
  author = {Somuncu, Makbule Nihan and Zamani, Adil and Zamani, Ayse Gul and İnci, Ayşe and Yıldırım, Mahmut Selman},
  title = {Peripheral immune checkpoint gene expression as diagnostic biomarkers in idiopathic pulmonary fibrosis},
  journal = {Sarcoidosis vasculitis and diffuse lung diseases},
  year = {2026},
  volume = {43},
  number = {3},
  pages = {18872--18872},
  doi = {10.36141/svdld.2026.18872}
}
Kostenlos starten →